Detalhe da pesquisa
1.
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
Rheumatology (Oxford)
; 61(8): 3257-3268, 2022 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34864911
2.
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study.
Lancet Rheumatol
; 4(4): e262-e273, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38288922
3.
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Rheumatol Ther
; 8(2): 903-919, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33913086